Generali Asset Management SPA SGR Takes $12.94 Million Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Generali Asset Management SPA SGR acquired a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 24,795 shares of the medical equipment provider’s stock, valued at approximately $12,942,000.

Several other institutional investors and hedge funds have also bought and sold shares of ISRG. Atala Financial Inc purchased a new position in Intuitive Surgical in the fourth quarter worth about $25,000. Berbice Capital Management LLC purchased a new position in Intuitive Surgical in the fourth quarter worth about $26,000. BankPlus Trust Department purchased a new position in Intuitive Surgical in the fourth quarter worth about $28,000. Kohmann Bosshard Financial Services LLC purchased a new position in Intuitive Surgical in the fourth quarter worth about $31,000. Finally, MidAtlantic Capital Management Inc. purchased a new position in Intuitive Surgical in the third quarter worth about $33,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Trading Up 0.9 %

ISRG opened at $488.80 on Tuesday. The business’s fifty day simple moving average is $566.38 and its 200-day simple moving average is $531.96. Intuitive Surgical, Inc. has a 12-month low of $364.17 and a 12-month high of $616.00. The company has a market capitalization of $174.10 billion, a price-to-earnings ratio of 76.26, a PEG ratio of 5.85 and a beta of 1.43.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on ISRG shares. Stifel Nicolaus lifted their price objective on Intuitive Surgical from $525.00 to $610.00 and gave the company a “buy” rating in a research report on Thursday, December 5th. BTIG Research lifted their price objective on Intuitive Surgical from $535.00 to $561.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Citigroup lifted their price objective on Intuitive Surgical from $640.00 to $711.00 and gave the company a “buy” rating in a research report on Friday, January 24th. Barclays lifted their price objective on Intuitive Surgical from $610.00 to $674.00 in a research report on Monday, January 27th. Finally, Erste Group Bank raised Intuitive Surgical from a “hold” rating to a “buy” rating in a research report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $610.19.

Insider Transactions at Intuitive Surgical

In other news, CFO Jamie Samath sold 94 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $571.11, for a total value of $53,684.34. Following the completion of the transaction, the chief financial officer now directly owns 2,630 shares in the company, valued at $1,502,019.30. This trade represents a 3.45 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Amal M. Johnson sold 4,635 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total value of $2,626,191.00. Following the completion of the transaction, the director now owns 12,275 shares of the company’s stock, valued at approximately $6,955,015. The trade was a 27.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 33,754 shares of company stock worth $17,691,621 over the last three months. 0.90% of the stock is currently owned by insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.